CN1091363C - 脂肪掺合物 - Google Patents
脂肪掺合物 Download PDFInfo
- Publication number
- CN1091363C CN1091363C CN98812474A CN98812474A CN1091363C CN 1091363 C CN1091363 C CN 1091363C CN 98812474 A CN98812474 A CN 98812474A CN 98812474 A CN98812474 A CN 98812474A CN 1091363 C CN1091363 C CN 1091363C
- Authority
- CN
- China
- Prior art keywords
- acid
- fat blend
- gamma
- fat
- parinaric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 235000019197 fats Nutrition 0.000 claims abstract description 86
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 33
- 239000000194 fatty acid Substances 0.000 claims abstract description 33
- 229930195729 fatty acid Natural products 0.000 claims abstract description 33
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 32
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 31
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 31
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 31
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims abstract description 31
- 229960002733 gamolenic acid Drugs 0.000 claims abstract description 28
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims abstract description 27
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims abstract description 27
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 24
- 235000010445 lecithin Nutrition 0.000 claims abstract description 24
- 239000000787 lecithin Substances 0.000 claims abstract description 24
- 229940067606 lecithin Drugs 0.000 claims abstract description 24
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000036737 immune function Effects 0.000 claims abstract description 4
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 4
- 208000035475 disorder Diseases 0.000 claims abstract description 3
- 239000003925 fat Substances 0.000 claims description 82
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 claims description 37
- 239000003921 oil Substances 0.000 claims description 35
- 235000019198 oils Nutrition 0.000 claims description 35
- 239000002253 acid Substances 0.000 claims description 29
- 125000001931 aliphatic group Chemical group 0.000 claims description 28
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 22
- 229940114079 arachidonic acid Drugs 0.000 claims description 22
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 235000021342 arachidonic acid Nutrition 0.000 claims description 11
- 210000000936 intestine Anatomy 0.000 claims description 10
- 235000016709 nutrition Nutrition 0.000 claims description 10
- 230000035764 nutrition Effects 0.000 claims description 10
- 210000002784 stomach Anatomy 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 7
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 230000006020 chronic inflammation Effects 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 230000004130 lipolysis Effects 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 235000021067 refined food Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 235000021487 ready-to-eat food Nutrition 0.000 claims 1
- 235000005911 diet Nutrition 0.000 abstract description 4
- 208000017667 Chronic Disease Diseases 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 abstract 2
- 230000000378 dietary effect Effects 0.000 abstract 2
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002366 lipolytic effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 6
- 235000021056 liquid food Nutrition 0.000 description 6
- 235000021323 fish oil Nutrition 0.000 description 5
- -1 20-3w6) Chemical compound 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241001072256 Boraginaceae Species 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000002030 Ethulia conyzoides Species 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000010499 rapseed oil Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000221030 Oenothera odorata Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000220151 Saxifragaceae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241001180933 Trichodesma <angiosperm> Species 0.000 description 1
- 241001083575 Trichodesma calycosum Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000021476 total parenteral nutrition Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000010913 used oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pediatric Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Edible Oils And Fats (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fats And Perfumes (AREA)
- Lubricants (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及含有多不饱和脂肪酸的油、脂肪和/或卵磷脂基脂肪掺合物。本发明脂肪掺合物的特点是每克脂肪酸总量中含10-500毫克γ-亚麻酸、十八碳四烯酸和二十碳五烯酸。γ-亚麻酸和二十碳五烯酸各占这三种脂肪酸总量的20-50%重量,十八碳四烯酸占这三种脂肪酸总量的15-50%重量。本发明的脂肪掺合物可加入到营养或医药产品中,特别是疗效食品中。本发明的脂肪掺合物特别适用于治疗患慢性/炎症疾病、脂质代谢紊乱、免疫功能衰退和/或肠胃道脂肪分解能力有限等疾病的病人。
Description
本发明涉及含多不饱和脂肪酸的油、脂肪和/或卵磷脂基脂肪掺合物、含上述脂肪掺合物的营养或药物组合物以及上述脂肪掺合物和营养或药物组合物的用途。
众所周知,人体能内源合成一些饱和脂肪酸和单不饱和脂肪酸,包括硬脂酸(C18-0)和油酸(C18-1w9),但人体不能内源合成必需的多不饱和脂肪酸,如亚油酸(18-2w6)和γ-亚麻酸(C18-3w3),从而必须与食品一起供应这些脂肪酸。因此,这些脂肪酸称为必需的脂肪酸。
然后在人体脂肪酸代谢中通过链延长或去饱和可以由这些必需的脂肪酸合成许多链更长(C20和C22)和不饱和度更高的脂肪酸。由亚油酸(C18-2w6)衍生的脂肪酸称为w6族脂肪酸,而由γ-亚麻酸衍生的脂肪酸称为w3族脂肪酸。这些多不饱和脂肪酸在英语中也称多不饱和脂肪酸或PUFA。另外,对于本申请中所用的缩写或名称可参见William W.Christie,Pergamon Press,1973出版的“脂质分析”。
上述的多不饱和脂肪酸是人体中所有细胞膜的结构成分。一些w3和w6族中的特定脂肪酸特别重要,因为它们可合成特定的分子。这些脂肪酸总称为类花生四烯酸(eicosanoid)。
集合名词类花生四烯酸目前理解为参与人体内各种调节过程的有高生理活性的激素样化合物的非常多种多样的复杂的混合物。类花生四烯酸主要来源于w6和w3去饱和的C20前体脂肪酸二高(dihomo)-γ-亚麻酸(DGLA,20-3w6)、花生四烯酸(AA,20-4w6)、二十碳四烯酸(20-4w3)和二十碳五烯酸(EPA;20-5w3)。
由多不饱和脂肪酸形成的类花生四烯酸的生物作用是非常不同的,取决于类花生四烯酸来源于w6族脂肪酸还是来源于w3族脂肪酸。一般来说,w3族类花生四烯酸具有抗炎作用,而w6族花生四烯酸的类花生四烯酸具有促炎(pro-inflammatorisch)特性。
由于饮食习惯和饮食方式,特别在西方国家,目前人体细胞膜脂质中的花生四烯酸的含量正在不断增加,因此更多地合成了由花生四烯酸产生的且具有促炎作用的类花生四烯酸。
最近试图通过有目的地经饮食摄入特定的多不饱和脂肪酸来对各种慢性炎症和脂质代谢紊乱的病症产生积极影响。例如,EP-A 0756827和EP-A0764405描述了服用含月见草油和/或鱼油的脂肪混合物或脂肪掺合物来改善免疫系统。DE-A3924607推荐使用含鱼油的营养品来降低高脂血症病人的血压。EP-A 0457950揭示用药物组合物中的十八碳四烯酸来治疗炎症疾病。
目前市场上已有用于肠内给予的脂肪乳液供应。这种脂肪乳液以γ-亚麻酸(GLA)和二十碳五烯酸(EPA)为必需的脂肪酸,有些产品也含有十八碳四烯酸(Stearidonsaure)(SA)。这种脂肪乳液用于改善免疫系统。
然而,在所有上述文献描述的产品或市场上出售的产品中,所用的多不饱和脂肪酸呈相互不平衡的比例。
本发明的目的是提供改进的脂肪掺合物(fat blend)和含有它的营养或药物组合物。用这种脂肪掺合物和营养或药物组合物可以最佳地影响脂肪酸代谢,特别是类花生四烯酸的代谢,从而通过服用这种脂肪掺合物或食物可以明显改善患各种疾病的病人的症状和临床问题。
本发明的目的可以用权利要求书中所述的脂肪掺合物或含有上述脂肪掺合物的营养食品达到。
现已令人惊奇地发现,通过给予相互呈特定、平衡比例的多不饱和脂肪酸γ-亚麻酸(GLA)、二十碳五烯酸(EPA)和十八碳四烯酸(SA)可以有效和最佳地影响花生四烯酸的类花生四烯酸代谢。因此要求保护GLA和EPA各占这三种脂肪酸总量20-50%重量,SA占这三种脂肪酸总量15-50%重量的脂肪掺合物。另外,每克脂肪酸总量(所有脂肪酸的总和)中共含10-500毫克这三种脂肪酸。
如果按要求保护的用量和比例服用上述的三种脂肪酸,则对形成具有促炎作用的花生四烯酸的类花生四烯酸产生不利影响。另外,类花生四烯酸的生理平衡倾向于抗炎和降脂作用。而且,用本发明的脂肪掺合物可以刺激和改善与发育或疾病有关的胃肠道脂质分解能力的降低。
因此,本发明提供某些多不饱和脂肪酸含量高且相互呈特定比例的脂肪掺合物。患有急性和慢性炎症、自身免疫疾病、代谢紊乱(高脂血症)、免疫功能衰退和/或肠胃道脂肪分解能力有限的病人可以服用本发明的脂肪掺合物或含有这种脂肪掺合物的食品。以下更详细地说明本发明要求主题的应用范围。
在本发明的脂肪掺合物中,脂肪酸较好以所用油、脂肪和卵磷脂原料的结合形式(特别是甘油三酯或磷脂)存在,这些脂肪酸也可全部或部分以游离脂肪酸、酯(如简单的烷基酯,如乙酯)或盐的形式存在。也可使用酯交换后的脂肪酸。因此,例如本发明的脂肪掺合物中可以补充这种游离脂肪酸、简单的脂肪酸酯或脂肪酸盐。本发明的掺合物甚至仅由这些游离脂肪酸、简单脂肪酸酯和/或脂肪酸盐组成。因此这种掺合物应称为脂肪酸掺合物。
本发明的脂肪掺合物较好是含有不同的油、脂肪和/或卵磷脂。因此,本发明的脂肪掺合物可包括不含或仅含少量多不饱和脂肪酸的不同的油、脂肪和卵磷脂。为了在本发明的脂肪掺合物中加入多不饱和脂肪酸,可以将上述油、脂肪和/或卵磷脂与含有多不饱和脂肪酸的油、脂肪和卵磷脂混合。
上述的油、脂肪和/或卵磷脂可以是常规的油、脂肪和/或卵磷脂,如动物油和植物油。然而,也可使用微生物和/或合成来源的油、脂肪和卵磷脂以及新开发的原料。也可使用将来开发的原料,因为使用何种原料仅取决于它们含有所述量和比例的特定脂肪酸。
按照一个优选的实施方式,脂肪酸GLA、SA和EPA共占每克脂肪酸总量中的10-100毫克,另外,GLA和EPA分别占这三种脂肪酸总和的35-45%重量,SA占15-25%重量。GLA和EPA较好各占这三种脂肪酸总量的约40%重量,SA较好占这三种脂肪酸总量的约20%重量。如果在本申请中揭示一个范围,则也揭示了该范围内的所有中间值。因此,10-100毫克或10-500毫克这种表达方式仅是这些范围内所有值的简略表达方式,特别是所有整数值的表达方式,如10、11、12、13、15、...30、31、32、33...65、66、67、68...85、...104、105、106、...150、151、152、...187、188、189、190、...215、216、217、...241、242、243、...268、269、270...、280...290、...300、301、302、303、304...、310...、320...、330...、340...、350...、360、361...、370...、380...、390...、400...、410...、415、416、417...、420...、430...、 440...、450...、460...、470...、480...、490、491...,495、496...。这同样也适用于重量百分数范围15-50%重量,35-45%重量以及15-25%重量。因此,也至少揭示了这些范围内的所有整数值,如15、18、21、24、27、28、31、33、37、39、40、42、44、47和49。另外,也包括较大范围中的所有较小范围。
上述情况也适用于本申请文件中以“%能量”形式要求保护的脂肪含量和要求保护的卵磷脂重量百分数值。因此,本发明中也揭示了这些范围端点值间的所有整数值。
在一个优选的实施方式中,脂肪掺合物也含有花生四烯酸(AA)。GLA+SA+EPA的总和与AA之比至少为10∶1。
在另一个优选的实施方式中,卵磷脂最多占总脂质(油、脂肪和卵磷脂的总和)的40%重量,较好占1-10%重量。
在另一个优选的实施方式中,脂肪掺合物中磷脂型的脂肪酸GLA、SA和EPA的总和在每克脂肪酸总量中最多占120毫克,较好在每克脂肪酸总量中占0.05-50毫克。这些磷脂型脂肪酸在每克脂肪酸总量中例如可占0.05、0.1、0.5、1、2、3、4、5、6、7、8、9和10毫克。在这种实施方式中同样也揭示了两端值之间的所有范围。
如上所述,本发明的脂肪掺合物可通过按上述数量比将动物、植物、微生物和/或合成的油、脂肪和/或卵磷脂混合在一起制备。
例如,单子叶和双子叶植物的“常规”油(如椰子油、棕榈坚果油、棕榈油、大豆油、向日葵油、菜油)可用作植物油。为了有目的地提高γ-亚麻酸(GLA)和十八碳四烯酸(SA)的含量,可使用“特别”的植物油,如琉璃苣油、月苋草油、蓝蓟油(echiuma oil)、毛束草油(trichodesma oil)以及用其它植物(如紫草科、玄参科、柳叶菜科和虎耳草科植物)种子的油。另外,例如可以使用用化学方法或酶法制得的富含GLA和SA的浓缩物以及用色谱分离法由上述来源制得的分离物。例如可以把蛋黄油、鱼油和海洋哺乳动物油、用化学方法或酶法制得的富含二十碳五烯酸或十八碳四烯酸的浓缩物以及用色谱分离法由上述原料分离得到的分离物用作动物脂肪和油。另外,可以使用含有γ-亚麻酸、十八碳四烯酸和二十碳五烯酸的微生物或合适海藻来源的油或脂肪、真菌油以及由上述原料制得的浓缩物。
另外,含GLA、SA和EPA的特定卵磷脂可用于本发明的脂肪掺合物中。其中可以列举蛋黄卵磷脂(较好是通过改良喂养具有w3-PUFA强化脂肪酸谱的蛋黄卵磷脂)、其它来源于鱼、海洋哺乳动物或微生物的含有w3-PUFA的天然卵磷脂以及已用化学法或酶法富集了GLA、SA和EPA(较好是甘油主链上sn-2位上)的卵磷脂。另外,中链甘油三酯(MCT)可用于要求保护的脂肪掺合物中。本申请中所用的术语“脂肪、油和卵磷脂”是指工艺上的原料。另一方面,磷脂和甘油三酯之类的术语是指化学物质。因此,油可以含有磷脂(通常称为卵磷脂),卵磷脂可以含有甘油三酯。特别是脱泥(deslime)或脱卵磷脂的市售油可适用作本发明中的油。当然,也可根据需要使用未经处理的原料油。
如下表1列出了通过混合用于制备本发明各种优选的脂肪掺合物的原料,即脂肪、油和卵磷脂。表2列出了表1中所示实例的脂肪酸组合物。在本申请中,术语“掺合物”是术语“混合物”的同义词。
表1:脂肪掺合物实例的组成
(数据按%重量计)原料 掺合物A 掺合物B 掺合物C 掺合物D 掺合物E 掺合物FMCT脂 30.0 30.0 30.0 -- 30.0 30.0肪棕榈油 26.0 16.5 20.0 26.0 26.0 26.0大豆油 16.5 11.5 8.0 16.5 17.5 13.5椰子油 30.0 --琉璃苣油 8.0 10.0 12.0 -- -- --蓝蓟油 11.0 13.0 18.0 19.0 19.0 19.0鱼油A -- 16.0 -- -- -- --鱼油B 6.5 -- 10.0 6.5 6.5 6.5蛋脂质/ 2.0 -- 2.0 2.0 1.0 5.0蛋卵磷脂鱼卵磷脂 3
表2
表1所示脂肪掺合物的脂肪酸组成
(如果没有另作说明,数据的单位为%重量)参数 掺合物A 掺合物B 掺合物C 掺合物D 掺合物E 掺合物F8-0 17.2 16.5 16.5 2.5 16.5 16.510-0 12.0 13.3 13.3 1.9 13.3 13.312-0 0.4 0.1 0.1 13.9 0.2 0.214-0 0.4 1.4 0.3 5.7 0.4 0.416-0 14.1 13.0 11.7 16.6 13.8 14.318-0 硬胇酸 2.7 2.5 2.6 3.6 2.6 3.218-1w9 油酸 19.2 15.8 16.8 21.5 19.4 19.618-2w6 亚油酸 17.2 15.2 15.1 15.8 15.6 14.018-3w6 γ-亚麻酸(GLA) 3.1 3.8 4.8 2.4 2.4 2.418-3w3 α-亚麻酸 4.2 4.5 5.7 6.4 6.5 6.318-4w3 十八碳四烯酸(SA) 1.6 2.1 2.5 2.5 2.5 2.520.3w6 二高-γ-亚麻酸DGLA) 0.02 0.04 0.05 0.02 0.02 0.0320-4w6 花生四烯酸(AA) 0.2 0.23 0.2 0.2 0.1 0.320-5w3 二十碳五烯酸(EPA) 3.0 3.2 4.7 3.0 3.0 3.022-6w3 二十二碳六烯酸 1.0 2.9 1.5 1.0 0.9 1.2w6与w3的总比例 2.1∶1 1.5∶1 1.4∶1 1.4∶1 1.4∶1 1.3∶118-3w6+18-4w3+20-5w3与20- 38.5∶1 39.3∶1 51.9∶1 39.5∶1 79.0∶1 26.3∶14w6之比∑A:18-3w6+18-4w3+20-5w3 7.7 9.1 11.9 7.9 7.9 7.918-3w6(%∑A) 40.3 41.7 39.9 30.4 30.4 30.418-4w3(%∑A) 20.8 23.0 21.2 31.7 31.7 31.720-5w3(%∑A) 39.0 35.4 38.9 38.0 38.0 38.0
根据技术状态,本发明的脂肪掺合物也可加入营养或药物组合物中。这也包括使用脂肪掺合物本身或它的微胶囊型组分。这种食品即营养品或药物组合物的其它组分也可以是已知的,且具有所需的性质,满足所需的要求。它较好是脂肪乳液、即食食物、液体食物、再生粉状食品或可再生的粉状食品。这些食品特别适用于肠胃外使用、肠胃内服用和/或口服。然而,它们也可以是压成块的加工食品和易被涂开的糊料。
本发明的液体食物和可再生粉状食物特别适用于肠胃外使用、肠胃内服用和/或口服。它们的脂肪含量较好为10-55%能量。能量密度较好为0.5-3.0千卡/毫升。另外,脂肪含量最好为25-40%能量,能量密度最好为1.1-1.4千卡/毫升。每1500毫升流质食品中共含脂肪酸γ-亚麻酸、十八碳四烯酸和二十碳五烯酸0.5-30克。每1500毫升流质食品中较好共含γ-亚麻酸、十八碳四烯酸和二十碳五烯酸1-10克。
本发明的营养食品不仅含有上述的脂肪混合物即脂肪掺合物,而且含有其它产物,如动物及/或植物蛋白质,如牛奶、乳清、豌豆、小麦和/或大豆,可为复合物形式及/或水解蛋白形式,可以加入或不加入不同数量比的游离氨基酸和/或二肽、以及碳水化合物(麦芽糖糊精)、维生素、粗糙食物、矿物质、微量元素、胆碱、牛磺酸、肉碱、肌醇和核苷酸和任选的水。如有需要,可将这些额外的组分与脂肪掺合物混合。
如下表3列出了本发明的一些可加入液体食物中的脂肪掺合物的脂质和脂肪酸含量。表4列出了本发明各种液体食物的组成值。表5列出了本发明脂肪乳液的配方实例。
表3:含有本发明脂肪掺合物的液体食物实例中的脂质和脂肪酸含量
(如果不另作说明,数据按毫克/1500毫升计)参数 单位 掺合物A 掺合物C 掺合物F总能量 千卡 1875 1875 1875总脂肪 %能量 25.0 35.0 25.0 35.0 25.0 35.0
克 52.1 72.9 52.1 72.9 52.1 72.9磷脂含量 % 2 2 5MCT % 30.0 30.0 30.0LA 18-2w6 毫克 9115 12760 7865 11010 7292 10208GLA 18-3w6 毫克 1615 2260 2479 3471 1250 1750ALA 18-3w3 毫克 2188 3063 2964 4149 3281 4594SA 18-4w3 毫克 833 1167 1318 1845 1302 1823DGLA 20-3w6 毫克 10 15 16 22 16 22AA 20-4w6 毫克 104 146 120 168 156 219EPA 20-5w3 毫克 1563 2188 2422 3391 1563 2188DHA 22-6w3 毫克 521 729 755 1057 625 875∑18-3w6+18- 毫克 4010 5615 6234 8728 4115 57604w3+20-5w3(总和)
表4:本发明液体食物实例的组成
(每个实例中的数据以100毫升基准)
实施例1 实施例2 实施例3能量 千卡 125 100 200蛋白质 %能量 24 24 24蛋白质 克 7.5 6 12谷氨酰胺 克 1.51 1.2 2.4精氨酸 克 0.87 0.70 1.40脂肪 %能量 30 30 30脂肪 克 4.2 3.3 6.6卵磷脂 克 0.084 0.066 0.132碳水化合物 %能量 46 46 46
克 14.4 11.5 23.0粗糙食物 克 0-0.9 0-7.2 0-14.4维生素、矿物 完全平衡 完全平衡 完全平衡质和微量元素硒 微克 2-15 2-15 2-15维生素A mgRE 0.05-0.3 0.05-0.3 0.05-0.3维生素C 毫克 4-35 4-35 4-35维生素E mgTE 0.5-15 0.5-15 0.5-15β-胡萝卜素 毫克 0-1.5 0-1.5 0-1.5其它物质:胆碱 毫克 10-100 10-100 10-100牛磺酸 毫克 0-50 0-50 0-50肉碱 毫克 0-20 0-20 0-20肌醇 毫克 0-30 0-30 0-30水 至100毫升 至100毫升 至100毫升
表5:要求保护的脂肪乳液的实例
(数据以克/100毫升为单位)
含量 含量 组分 %分布
3.0 6.0 MCT脂肪 30%
3.0 6.0 低芥酸菜子油 30%
1.2 2.4 鱼油B(45/10) 12%
1.8 3.6 琉璃苣油 18%
1.0 2.0 蓝蓟油 10%总和: 总和: 总和:
10 20 油和脂肪 100%
1.2 1.2 蛋卵磷脂
2.25 2.25 甘油USP至100毫升 至100毫升 水(注射用水)
本发明的脂肪掺合物和含有这种脂肪掺合物的本发明营养或药物组合物特别适用于治疗患有如下疾病的病人:
1.患有急性和慢性炎症、自身免疫疾病和免疫功能衰退的病人,如患有克罗恩氏病、牛皮癣、慢性多发性关节炎、风湿病的病人;神经变质性疾病病人、肺病病人、手术后的病人、艾滋病人、肿瘤病人、囊性纤维变性病人、败血症病人、高危病人(有感染危险,为避免/减少医院传染)、危急病人(如多发生损伤、外伤后、post-aggression代谢、代谢应激)、患有全身炎症综合征(SIRS:“全身炎症反应综合征”)、多发性器官衰竭和/或为避免多发性器官衰竭、进行血管成形或旁路手术(再狭窄、植入物闭塞)后的冠状动脉病人支持器官移植病人的免疫抑制治疗以及糖尿病人。
2.脂质代谢紊乱病人:
如患有心血管疾病、高脂血症、代谢综合征等的病人。
3.肠胃道脂肪分解能力有限的病人
如患有克罗恩氏病、溃疡性结肠炎、遗传性(囊性纤维变性或Schwachmann综合征)与发育有关的(新生儿)或获得性胰腺外分泌不足的病人、患有短肠综合征或肠胃道被辐射或抑制细胞的组合物损伤的病人、短期或长期全肠胃外营养后以及患有肝脏或胆道疾病(慢性肝炎、酒精综合征、脂肪肝)的病人。
Claims (16)
1.脂肪掺合物,它包含选自油、脂肪、卵磷脂、脂肪酸及其盐或酯的组分,且含有多不饱和脂肪酸,其特征在于每克脂肪酸总量中共含10-500毫克γ-亚麻酸、十八碳四烯酸和二十碳五烯酸,
γ-亚麻酸和二十碳五烯酸各占这三种脂肪酸总量的20-50%重量,十八碳四烯酸占这三种脂肪酸总量的15-50%重量。
2.如权利要求1所述的脂肪掺合物,其特征在于每克脂肪酸总量中含10-100毫克γ-亚麻酸、十八碳四烯酸和二十碳五烯酸,
γ-亚麻酸和二十碳五烯酸各占这三种脂肪酸总量的35-45%重量,十八碳四烯酸占这三种脂肪酸总量的15-25%重量。
3.如权利要求2所述的脂肪掺合物,其特征在于γ-亚麻酸和二十碳五烯酸各占这三种脂肪酸总量的40%重量,十八碳四烯酸占这三种脂肪酸总量的20%重量。
4.如上述权利要求1所述的脂肪掺合物,其特征在于它含有花生四烯酸,且γ-亚麻酸、十八碳四烯酸和二十碳五烯酸的总和与花生四烯酸之比至少为10∶1。
5.如上述权利要求1所述的脂肪掺合物,其特征在于磷脂的含量最多占油、脂肪和卵磷脂的总脂质量的40%重量。
6.如权利要求5所述的脂肪掺合物,其特征在于磷脂占总脂质量的1-10%重量。
7.如上述权利要求1所述的脂肪掺合物,其特征在于所述脂肪掺合物中以磷脂存在的脂肪酸γ-亚麻酸、十八碳四烯酸和二十碳五烯酸的总和最多为120毫克/克脂肪酸总量。
8.如上述权利要求7所述的脂肪掺合物,其特征在于所述脂肪掺合物中以磷脂存在的脂肪酸γ-亚麻酸、十八碳四烯酸和二十碳五烯酸的总和为0.05-50毫克/克脂肪酸总量。
9.营养或药物组合物,其特征在于它含有如权利要求1-8中任一项所述的脂肪掺合物。
10.如权利要求9所述的营养或药物组合物,其特征在于它是脂肪乳液、即食食品、流质食品、再生或待再生粉状食品。
11.如权利要求10所述的营养或药物组合物,其特征在于它是胃肠外使用、肠内服用和/或口服的,压成块的加工食品或可涂布的糊状物。
12.如权利要求10所述的组合物,它们是供胃肠外使用、肠内服用和/或口服的流质食品或再生粉状食品,其特征在于10-55%能量来自所含的脂肪,能量密度为0.5-3.0千卡/毫升。
13.如权利要求12所述的组合物,其特征在于25-40%能量来自所含的脂肪,能量密度为1.1-1.4千卡/毫升。
14.如权利要求9-13中任一项所述的组合物,它们是流质食品或再生粉状食品,其特征在于每1500毫升流质食品中共含脂肪酸γ-亚麻酸、十八碳四烯酸和二十碳五烯酸0.5-30克。
15.如权利要求14所述的组合物,其特征在于每1500毫升流质食品中共含γ-亚麻酸、十八碳四烯酸和二十碳五烯酸1-10克。
16.如权利要求1-8中任一项所述的脂肪掺合物或权利要求9-15中任一项所述的营养或药物组合物在制备治疗慢性炎症性疾病、脂质代谢紊乱、免疫功能衰退和/或肠胃道脂肪分解能力有限的药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19757414A DE19757414A1 (de) | 1997-12-23 | 1997-12-23 | Fettmischung |
DE19757414.9 | 1997-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1282223A CN1282223A (zh) | 2001-01-31 |
CN1091363C true CN1091363C (zh) | 2002-09-25 |
Family
ID=7853100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98812474A Expired - Fee Related CN1091363C (zh) | 1997-12-23 | 1998-12-22 | 脂肪掺合物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7045143B1 (zh) |
EP (1) | EP1041896B1 (zh) |
JP (1) | JP2001526908A (zh) |
CN (1) | CN1091363C (zh) |
AT (1) | ATE213391T1 (zh) |
AU (1) | AU758079B2 (zh) |
BR (1) | BR9814467A (zh) |
CA (1) | CA2316298C (zh) |
DE (2) | DE19757414A1 (zh) |
DK (1) | DK1041896T3 (zh) |
ES (1) | ES2173673T3 (zh) |
HK (1) | HK1033541A1 (zh) |
NO (1) | NO316302B1 (zh) |
NZ (1) | NZ505608A (zh) |
WO (1) | WO1999033355A2 (zh) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19757414A1 (de) | 1997-12-23 | 1999-07-01 | Nutricia Nv | Fettmischung |
DE19914104A1 (de) * | 1999-03-23 | 2000-09-28 | Siegfried Seifert | Verfahren zur Verbesserung der körperlichen Erscheinung eines Menschen unter Verabreichung einer Fett-Eiweiß-Diät |
US6340705B1 (en) * | 1999-09-10 | 2002-01-22 | Monsanto Technology, Llc | Use of α-linolenic acid metabolites for treatment or prevention of cancer |
WO2001024812A1 (en) * | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
US6667064B2 (en) * | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
EP1392278A4 (en) * | 2001-05-14 | 2005-05-04 | Martek Biosciences Corp | PRODUCTION AND USE OF A LIPID-RICH POLAR FRACTION CONTAINING STEARIDONIC ACID AND GAMMA-LINOLENIC ACID EXTRACTED FROM SEEDS AND MICROORGANISMS |
WO2002092779A2 (en) * | 2001-05-17 | 2002-11-21 | Pilot Therapeutics, Inc. | Method for enriching tissues in long chain polyunsaturated fatty acids |
MXPA04008711A (es) | 2002-03-08 | 2004-12-13 | Monsanto Technology Llc | Tratamiento y prevencion de trastornos inflamatorios. |
DE10254584A1 (de) * | 2002-11-22 | 2004-06-09 | HORST HEIRLER PROJEKTE für Ernährung, Medizin, Ökologie | Verwendung von mittelkettigen Triglyceriden (MCT) zur ernährungsphysiologischen Optimierung des Fettsäurenspektrums in einem diätetischen Lebensmittel für Diabetiker |
DE10361667A1 (de) * | 2003-12-30 | 2005-07-28 | Omega For Life Gmbh | Neuartige Fettpulver |
EP1723951A1 (en) * | 2005-04-21 | 2006-11-22 | N.V. Nutricia | Nutritional supplement with oligosaccharides for a category of HIV patients |
WO2006052134A2 (en) * | 2004-11-12 | 2006-05-18 | N.V. Nutricia | Food composition comprising a protein- and a lipid fraction for rapidly attenuating inflammatory responses |
US20090318394A1 (en) * | 2004-11-19 | 2009-12-24 | Julie Nauroth | Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same |
US7893106B2 (en) * | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
CN101102988B (zh) * | 2004-11-19 | 2011-12-14 | 马泰克生物科学公司 | 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法 |
WO2007063143A1 (es) * | 2005-11-30 | 2007-06-07 | Katry Inversiones, S.L. | Mezcla de lipidos y su utilización para preparar un producto destinado a la adminitracion enteral u oral |
ATE509624T1 (de) * | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
US20090320148A1 (en) * | 2006-01-31 | 2009-12-24 | Martek Biosciences Corporation | Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same |
KR20090007407A (ko) * | 2006-04-11 | 2009-01-16 | 마텍 바이오싸이언스스 코포레이션 | 장쇄 다중불포화 지방산을 포함하는 식품 제품 및 그의 제조 방법 |
GB0612671D0 (en) * | 2006-06-27 | 2006-08-09 | Shs Int Ltd | Nutritional formulation |
US20080089981A1 (en) * | 2006-10-17 | 2008-04-17 | N.V. Nutricia | Ketogenic diet |
CA2567879C (en) * | 2006-11-14 | 2013-03-26 | Thomas Greither | Nutritional food oil compositions and methods of making same |
GB2444896B (en) * | 2006-12-18 | 2010-05-19 | Nutraceuticals Ltd | Compositions comprising polyunsaturated fatty acids |
CN101663031A (zh) * | 2007-02-20 | 2010-03-03 | 马泰克生物科学公司 | 来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法 |
US8652508B2 (en) * | 2007-05-25 | 2014-02-18 | Children's Medical Center Corporation | Dietary formulations and methods for treatment of inflammation and other disorders |
CN101820754A (zh) * | 2007-10-04 | 2010-09-01 | 雀巢产品技术援助有限公司 | 用于增强认知功能的组合物与方法 |
KR101454060B1 (ko) * | 2007-11-29 | 2014-10-28 | 몬산토 테크놀로지 엘엘씨 | 증가된 수준의 유익한 지방산을 갖는 육제품 |
US20110027841A1 (en) * | 2007-12-21 | 2011-02-03 | Martek Biosciences Corporation | Method for preparation of oxylipins |
US20100266746A1 (en) * | 2009-04-16 | 2010-10-21 | Monsanto Technology Llc | Spread formulations including stearidonic acid |
US20120231142A1 (en) * | 2009-07-15 | 2012-09-13 | Solae, Llc | Omega-3 Fatty Acid Enriched Soups and Sauces |
EP2470028A4 (en) * | 2009-09-30 | 2015-01-14 | Solae Llc | FAT AND NUT BUTTER ENRICHED WITH OMEGA-3 FATTY ACIDS |
WO2011071365A1 (en) * | 2009-12-07 | 2011-06-16 | N.V. Nutricia | Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding |
US20120277316A1 (en) * | 2010-01-19 | 2012-11-01 | University of Tennesse Research Foundation a university | Methods and compositions for treating and preventing parenteral nutrition associated liver disease |
US8372465B2 (en) | 2010-02-17 | 2013-02-12 | Bunge Oils, Inc. | Oil compositions of stearidonic acid |
ES2875458T3 (es) * | 2010-12-29 | 2021-11-10 | Abbott Lab | Producto nutricional para uso en la reducción de la incidencia de enterocolitis necrosante en un lactante, niño pequeño o niño |
US20120252888A1 (en) * | 2011-03-29 | 2012-10-04 | Palupa Medical Ltd. | Compositions and Methods for Treating Neurologic Disorders |
WO2012138212A1 (en) | 2011-04-06 | 2012-10-11 | N.V. Nutricia | Food composition for intra-operative tube feeding |
US8728546B1 (en) | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
US20150157048A1 (en) * | 2013-12-11 | 2015-06-11 | Mead Johnson Nutrition Company | Nutritional compositions containing stearidonic acid and uses thereof |
US11419350B2 (en) | 2016-07-01 | 2022-08-23 | Corbion Biotech, Inc. | Feed ingredients comprising lysed microbial cells |
CN109527123A (zh) * | 2018-12-14 | 2019-03-29 | 大连大学 | 一种对慢性肠炎具有改善作用的调和油 |
CN112891304B (zh) * | 2020-10-14 | 2022-06-10 | 麦孚营养科技有限公司 | 一种高能量密度的脂肪乳剂及其制备方法和其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
CN1099610A (zh) * | 1993-03-19 | 1995-03-08 | 斯科舍集团有限公司 | 用于吸烟者的制剂 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3924607A1 (de) * | 1989-07-21 | 1991-01-24 | Singer Peter Dr Sc Med | Diaetetisches nahrungs- oder genussmittel |
EP0457950B1 (fr) * | 1990-05-23 | 1993-10-20 | Societe Des Produits Nestle S.A. | Utilisation de l'acide stéaridonique pour le traitement des maladies inflammatoires |
GB9026648D0 (en) * | 1990-12-07 | 1991-01-23 | Efamol Holdings | Nutrition |
US5922345A (en) * | 1990-12-07 | 1999-07-13 | Scotia Holdings Plc | Nutrition |
AU683027B2 (en) * | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
US5714472A (en) | 1993-12-23 | 1998-02-03 | Nestec Ltd. | Enternal formulation designed for optimized nutrient absorption and wound healing |
GB9506837D0 (en) * | 1995-04-03 | 1995-05-24 | Scotia Holdings Plc | Triglycerides |
DE19528461A1 (de) | 1995-08-03 | 1997-02-06 | Braun Melsungen Ag | Präparat zur Ernährung |
WO1997035488A1 (en) * | 1996-03-26 | 1997-10-02 | Gist-Brocades B.V. | Late addition of pufa in infant formula preparation process |
US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
DE69622722T2 (de) * | 1996-11-20 | 2003-02-27 | Nutricia Nv | Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms |
DE19757414A1 (de) | 1997-12-23 | 1999-07-01 | Nutricia Nv | Fettmischung |
-
1997
- 1997-12-23 DE DE19757414A patent/DE19757414A1/de not_active Withdrawn
-
1998
- 1998-12-22 WO PCT/EP1998/008409 patent/WO1999033355A2/de active IP Right Grant
- 1998-12-22 NZ NZ505608A patent/NZ505608A/xx not_active IP Right Cessation
- 1998-12-22 AT AT98966662T patent/ATE213391T1/de active
- 1998-12-22 CN CN98812474A patent/CN1091363C/zh not_active Expired - Fee Related
- 1998-12-22 DE DE59803153T patent/DE59803153D1/de not_active Expired - Lifetime
- 1998-12-22 EP EP98966662A patent/EP1041896B1/de not_active Expired - Lifetime
- 1998-12-22 CA CA002316298A patent/CA2316298C/en not_active Expired - Fee Related
- 1998-12-22 AU AU24162/99A patent/AU758079B2/en not_active Ceased
- 1998-12-22 ES ES98966662T patent/ES2173673T3/es not_active Expired - Lifetime
- 1998-12-22 US US09/581,520 patent/US7045143B1/en not_active Expired - Fee Related
- 1998-12-22 BR BR9814467-7A patent/BR9814467A/pt not_active Application Discontinuation
- 1998-12-22 JP JP2000526127A patent/JP2001526908A/ja active Pending
- 1998-12-22 DK DK98966662T patent/DK1041896T3/da active
-
2000
- 2000-06-22 NO NO20003265A patent/NO316302B1/no not_active IP Right Cessation
-
2001
- 2001-04-11 HK HK01102614A patent/HK1033541A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
CN1099610A (zh) * | 1993-03-19 | 1995-03-08 | 斯科舍集团有限公司 | 用于吸烟者的制剂 |
Also Published As
Publication number | Publication date |
---|---|
US7045143B1 (en) | 2006-05-16 |
EP1041896A2 (de) | 2000-10-11 |
AU758079B2 (en) | 2003-03-13 |
ATE213391T1 (de) | 2002-03-15 |
WO1999033355A2 (de) | 1999-07-08 |
EP1041896B1 (de) | 2002-02-20 |
DK1041896T3 (da) | 2002-06-17 |
NO20003265L (no) | 2000-06-22 |
NO316302B1 (no) | 2004-01-12 |
DE59803153D1 (de) | 2002-03-28 |
CA2316298C (en) | 2008-11-18 |
AU2416299A (en) | 1999-07-19 |
HK1033541A1 (en) | 2001-09-07 |
JP2001526908A (ja) | 2001-12-25 |
WO1999033355A3 (de) | 1999-09-16 |
DE19757414A1 (de) | 1999-07-01 |
CA2316298A1 (en) | 1999-07-08 |
BR9814467A (pt) | 2000-10-10 |
CN1282223A (zh) | 2001-01-31 |
NO20003265D0 (no) | 2000-06-22 |
ES2173673T3 (es) | 2002-10-16 |
NZ505608A (en) | 2002-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1091363C (zh) | 脂肪掺合物 | |
EP1296670B1 (en) | Therapeutic combinations of fatty acids | |
Calder et al. | Polyunsaturated fatty acids, inflammation and immunity | |
DE69534128T2 (de) | Verwendung von Laurinsäure oder vom einem C8-C16 Fettsäuremonoglyzerid zur Hemmung von Helicobacter | |
AU2004271928B2 (en) | Lipid system and methods of use | |
CA2147302C (en) | A lipid composition for normalizing injury | |
CA2549103A1 (en) | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof | |
NZ535549A (en) | Treatment and prevention of inflammatory disorders | |
KR20090045929A (ko) | 유아용 조제유에서 DPA(n-6) 오일의 용도 | |
EP1416812B1 (en) | Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level | |
AU2002325344A1 (en) | Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lilpid level | |
EP0490561B1 (en) | Nutrition | |
CA2039980A1 (en) | Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients | |
Suchner et al. | Immune modulation by polyunsaturated fatty acids during nutritional therapy: interactions with synthesis and effects of eicosanoids | |
JPH0823941A (ja) | 健康飲料 | |
WO2020248710A1 (zh) | 一种油脂组合物及其制备方法 | |
Simopoulos et al. | Omega-6/omega-3 essential fatty acid ratio: The scientific evidence | |
JP3947322B2 (ja) | 多価不飽和脂肪酸を含有する医薬組成物および健康食品 | |
OGUNLEIYE et al. | Effect of fish oil and safflower oil in common Japanese diet on human plasma fatty acid composition | |
CN113273613A (zh) | sn-2不饱和脂肪酸活性型结构脂组合物及其制备方法与用途 | |
CN115428767A (zh) | 高极长链饱和脂肪酸动物模型及其构建方法 | |
Wallace | Dietary fatty acids affect inflammatory mediator production by mirine and human macrophages and lymphocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20020925 Termination date: 20121222 |